Business

Mankind Pharma Aims To Raise Rs 4,700 crore through IPO

Mankind Pharma, backed by PE firm ChrysCapital, is in hopes to collect Rs 4,500-4,700 through an Initial Public Offering (IPO). The IPO is expected to go public at the end of this month or at the beginning of the following month.

According to a source close to the development, “The company is looking to launch the  IPO by the end of this month, depending on regulatory approvals. This would perhaps be one of the biggest IPOs of FY24 and will come at a time when fundraising from the capital markets is gaining steam. The firm is awaiting final approvals from the regulator.”

ChrysCapital and the company’s promoters will each dilute 2.5% of their ownership, and Capital International will sell 5% of its ownership through the inaugural stake sale. ChrysCapital currently owns 10% of the business, Capital International 11%, and the promoters own the remaining 79%.

As their investment tenure in the business is coming to an end, the PE investors, who are holding stakes through affiliated firms, are partially exiting, they added. ChrysCapital had sold Capital International an 11% stake in the business in 2015 for $200 million, and a consortium led by ChrysCapital subsequently purchased a 10% stake for about $350 million.

Draft Red Herring Prospectus (DRHP)

 

On September 15, 2022, the company submitted its DRHP for IPO to the market regulator Sebi. The DRHP stated that Mankind Pharma would sell 40 million shares in total, with the values being determined by a book-building procedure. The company’s promoters, including Chairman Ramesh Juneja, MD Rajeev Juneja, and CEO Sheetal Arora, will also sell their stakes in addition to the PE companies. The issuance is being managed by Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India, and JP Morgan India.

Mankind Pharma, one of the biggest distribution networks of medical representatives in the Indian pharmaceutical market, has established 36 brands in the pharmaceutical industry. Over 80% of physicians in India recommended its formulations during the fiscal year 2022.

Also Read: Johnson & Johnson Proposes Paying $9 Billion to Settle Talc Cancer claims

Malika Sahni

Recent Posts

Renowned Folk Singer Sharda Sinha Passes Away At 72; PM Modi Expresses Condolences

PM Modi expressed sorrow over Sinha’s death. "The passing of Sharda Sinha ji is deeply…

7 hours ago

US Election: India Confident Of Strong US Relations And Quad Continuity, Says Jaishankar

Jaishankar noted that the US-India relationship has flourished under both Democratic and Republican leadership, including…

7 hours ago

Sanskriti Diwas Marks 98th Birth Anniversary Of Kashiraj Dr Vibhuti Narayan Singh

Program coordinator Chakravarti Vijay Navad announced that 11 prominent individuals received the Kashiraj Dr. Vibhuti…

8 hours ago

Mallikarjun Kharge Slams ‘Batenge Toh Katenge’ Slogan During Jharkhand Campaign

Kharge emphasized that the BJP leaders promote divisive rhetoric as part of their agenda. He…

9 hours ago

Police Arrest Two In Fake Marriage Certificate Racket In Name Of Arya Samaj

DCP Nagar Abhishek Bharti revealed that five couples, including Shivani and Shrikant Yadav, recently filed…

10 hours ago

India And Nigeria Strengthen Counter-Terrorism Cooperation In Second Strategic Dialogue

Doval and Ribadu held detailed talks on challenges linked to terrorism and radicalization, including those…

10 hours ago